Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer
Combining enzalutamide with docetaxel is more effective than docetaxel alone for treating mCRPC after abiraterone and enzalutamide, providing better PSA-PFS and improved metastasis outcomes, along with better pain relief. Though the combination resulted in more adverse effects, no severe reactions (Grade 3 or higher) were observed, indicating good tolerability and clinical potential.
Authors
- Jianglei Zhang (ORCID: https://orcid.org/0009-0009-6696-2273)
- Jun Ouyang (ORCID: https://orcid.org/0000-0003-1509-0558)
- Yipeng Yu
- Chenkai Zhang (ORCID: https://orcid.org/0009-0004-1583-0506)
- Xuefeng Zhang (ORCID: https://orcid.org/0000-0002-6781-4274)
- Zhiyu Zhang (ORCID: https://orcid.org/0000-0002-4783-0082)
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.3389/fonc.2025.1608786
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Science and Technology Program of Suzhou